Format

Send to

Choose Destination
Nat Chem Biol. 2008 Aug;4(8):498-506. doi: 10.1038/nchembio.100. Epub 2008 Jul 11.

An integrated platform of genomic assays reveals small-molecule bioactivities.

Author information

1
Department of Genetics, Stanford University, Mail Stop-5120, Palo Alto, California 94305, USA.

Erratum in

  • Nat Chem Biol.2008 Oct;4(10):632.. StOnge, Robert P [corrected to St Onge,Robert P].

Abstract

Bioactive compounds are widely used to modulate protein function and can serve as important leads for drug development. Identifying the in vivo targets of these compounds remains a challenge. Using yeast, we integrated three genome-wide gene-dosage assays to measure the effect of small molecules in vivo. A single TAG microarray was used to resolve the fitness of strains derived from pools of (i) homozygous deletion mutants, (ii) heterozygous deletion mutants and (iii) genomic library transformants. We demonstrated, with eight diverse reference compounds, that integration of these three chemogenomic profiles improves the sensitivity and specificity of small-molecule target identification. We further dissected the mechanism of action of two protein phosphatase inhibitors and in the process developed a framework for the rational design of multidrug combinations to sensitize cells with specific genotypes more effectively. Finally, we applied this platform to 188 novel synthetic chemical compounds and identified both potential targets and structure-activity relationships.

PMID:
18622389
DOI:
10.1038/nchembio.100
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center